NCT02066636

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,428 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.

Conditions

• Non Small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
DRUG	Nivolumab

Timeline

• Start date: 2014-04-09
• Primary completion: 2021-10-06
• Completion: 2021-10-06
• First posted: 2014-02-19
• Last updated: 2022-10-27
• Results posted: 2022-10-27

Locations

134 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study